Back

Ferric carboxymaltose modulates metabolic and inflammatory pathways alongside erythropoiesis in heart failure: mechanistic insights from the AFFIRM-AHF

10 May 2026 (15:06 - 15:15)
Organised by: Logo
Congress Presentation Part of: Novel and targeted therapies: precision pharmacology in heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Niels Grote Beverborg

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Mavacamten to treat patients with obstructive HCM in Portugal: an interim analysis of the MAVA-PT cohort
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract
Presentation thumbnail
The influence of QRS duration and resynchronization status on the efficacy and safety of omecamtiv mecarbil in heart failure with reduced ejection fraction: the GALACTIC-HF trial
Assistant Professor M. Ruppert (Boston, US)
Abstract Slides Video
Presentation thumbnail
Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials
Doctor G. Mendieta Badimon (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Effect of aficamten compared with metoprolol in women versus men: analysis of MAPLE-HCM
Doctor X. Wang (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Novel and targeted therapies: precision pharmacology in heart failure
Video

The Event

Event poster

Heart Failure 2026

10 May 2026 15:06 CET
You may be interested in
thumbnail
Congress Presentation
Iron therapy
thumbnail
Congress Presentation
Treatment of iron deficiency in heart failure in 2023
thumbnail
Congress Session
IV iron: the story so far

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources